A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Exercise Tolerance in Subjects With Chronic Stable Angina.

Trial Profile

A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Exercise Tolerance in Subjects With Chronic Stable Angina.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2013

At a glance

  • Drugs Febuxostat (Primary)
  • Indications Angina pectoris
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Dec 2012 Actual initiation date changed from Apr 2012 to Jul 2012 as reported by ClinicalTrials.gov.
    • 01 Nov 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 04 Apr 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top